Tg Therapeutics 15min chart shows MACD Death Cross, Bollinger Bands Narrowing.

According to the technical analysis of Tg Therapeutics' 15-minute chart, a MACD Death Cross and narrowing Bollinger Bands have been observed as of September 22, 2022 at 15:00. This indicates that the stock price is likely to experience further downward momentum, with a decreasing magnitude of price fluctuations.

According to recent reports, B. Riley Securities has maintained its Buy rating for TG Therapeutics (TGTX) and raised the price target from $53.00 to $55.00, reflecting a 3.77% increase TGTX: B. Riley Securities Raises Price Target on TG Therapeutics | TGTX Stock News^[1]. The analyst responsible for this update, Mayank Mamtani, suggests that the increase aligns with recent market evaluations and strategic company developments. TG Therapeutics, a biopharmaceutical company focused on B-cell diseases, continues to be seen favorably within the market.

The company has received FDA approval for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) and is developing several promising drugs, including TG-1701, Azer-Cel, and TG-1801, for B-cell disorders TGTX: B. Riley Securities Raises Price Target on TG Therapeutics | TGTX Stock News^[1]. Geographically, TG Therapeutics generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Based on Wall Street analysts' forecasts, the average target price for TG Therapeutics is $42.00, with a high estimate of $55.00 and a low estimate of $11.00. The consensus recommendation from 9 brokerage firms is "Outperform," indicating a positive outlook for the company TGTX: B. Riley Securities Raises Price Target on TG Therapeutics | TGTX Stock News^[1].

Investors in TG Therapeutics have also been observing new options trading for the May 2026 expiration. A put contract at the $32.00 strike price has a current bid of $5.80, representing a potential yield boost of 18.12% if the contract expires worthless. Meanwhile, a call contract at the $34.00 strike price has a current bid of $6.30, offering a potential yield boost of 19.10% Interesting TGTX Put And Call Options For May 2026^[2].

Technical analysis of TG Therapeutics' 15-minute chart indicates a MACD Death Cross and narrowing Bollinger Bands as of September 22, 2022 at 15:00, suggesting further downward momentum with decreasing price fluctuations .